Accounting Manager
Braveheart Bio
Accounting Manager
Braveheart Bio
Develops cardiac myosin inhibitors for HCM
About us:
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
The role:
The Accounting Manager will own day-to-day accounting operations, support the month-end close process, and prepare clinical trial accruals for our fast-moving clinical-stage biotechnology company. Reporting to the Senior Director, Controller, this hands-on role will support internal controls, financial reporting, system implementations, and collaboration with finance, clinical operations, external vendors, and other cross-functional partners as Braveheart Bio continues to scale.
Key responsibilities:
Required experience & skills:
Preferred experience & skills:
Base Salary Range: $125,000 - $145,000
This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E‑Verify program to confirm employment authorization for all new hires.
To learn more about E-Verify please review this poster.
Develops cardiac myosin inhibitors for HCM
Braveheart Bio develops therapies for hypertrophic cardiomyopathy by in-licensing promising drug candidates and advancing them through late-stage clinical trials. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights, designed to reduce contractility in heart cells and improve heart performance. The company differentiates itself by pursuing a best-in-class profile with potential improvements in efficacy, safety, and dosing, supported by a high-profile leadership team and investors. Its goal is to bring an approved, globally accessible therapy for HCM that delivers meaningful clinical benefit.
Explore more opportunities at Braveheart Bio